Diffuse large B-cell lymphoma (DLBCL) is the most common form of aggressive non-Hodgkin lymphoma (NHL) in the United States, accounting for about 23% of all newly diagnosed cases of B-cell NHL. Effective standard treatment options for relapsed or refractory (R/R) DLBCL are extremely limited. An article published in Targeted Oncology in January reviews recent developments in the treatment spectrum for R/R DLBCL.
Recently approved agents include polatuzumab vedotin-piiq, an antibody-drug conjugate (approved by the FDA in 2019 for use in adults in combination with bendamustine and rituximab following at least two prior therapies); selinexor, a selective inhibitor of nuclear export (approved in 2020 for use in adults following at least two prior systemic therapies); and tafasitamab-cxix, a CD19-targeting monoclonal antibody (approved in 2020 for use with lenalidomide in adults with R/R DLBCL who are ineligible for ASCT).
Targeted therapies currently in development include bispecific T-cell engagers, CAR T-cell therapies, and inhibitors of PD-1 and BCL2. Work is also ongoing to develop diagnostics to further elucidate DLBCL driver mutations, which may lead to the development of new individually tailored therapies.